Home / Business and Economy / Trump's Drug Price Plan: India's Pharma Giants Unfazed
Trump's Drug Price Plan: India's Pharma Giants Unfazed
21 Dec, 2025
Summary
- US President Trump introduced Most Favored Nation pricing deals.
- The policy targets patented drugs, not generics.
- Indian drugmakers are unlikely to be immediately impacted.
US President Donald Trump recently unveiled his administration's Most Favored Nation (MFN) pricing policy, an initiative designed to reduce the cost of prescription drugs for Americans. This policy aims to link the prices paid for certain drugs in the US to the lowest prices available in other developed countries.
The move has prompted analysis regarding its potential impact on international pharmaceutical markets. Experts and industry analysts believe that Indian drug manufacturers are unlikely to experience immediate adverse effects from this new policy. This is largely because the MFN deals are primarily focused on patented, high-cost medications.
India serves as a critical supplier of generic drugs to the US market. Given that the MFN policy's focus is on patented drugs, its direct impact on India's significant generic drug exports is anticipated to be limited, suggesting that Indian pharmaceutical companies may continue their operations with minimal disruption.
